BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30227129)

  • 1. Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm.
    Spicer JD; Shewale JB; Nelson DB; Mitchell KG; Bott MJ; Vallières E; Wilshire CL; Vaporciyan AA; Swisher SG; Jones DR; Darling GE; Sepesi B
    Ann Thorac Surg; 2019 Jan; 107(1):277-284. PubMed ID: 30227129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
    Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy following induction therapy and surgery improves survival in N2-positive non-small cell lung cancer.
    White AA; Lee DN; Mazzola E; Kucukak S; Polhemus E; Jaklitsch MT; Mentzer SJ; Wee JO; Bueno R; Swanson SJ
    J Surg Oncol; 2021 Feb; 123(2):579-586. PubMed ID: 33259637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer.
    Drake JA; Portnoy DC; Tauer K; Weksler B
    Ann Thorac Surg; 2018 Oct; 106(4):959-965. PubMed ID: 29856974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.
    Amini A; Correa AM; Komaki R; Chang JY; Tsao AS; Roth JA; Swisher SG; Rice DC; Vaporciyan AA; Lin SH
    Ann Thorac Surg; 2012 Sep; 94(3):914-20. PubMed ID: 22819472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment rationale and design of the induction chemotherapy and adjuvant thoracic radiation in resectable N2-3A/3B non-small cell lung cancer (ICAT) study.
    Tsunezuka H; Inoue M
    Medicine (Baltimore); 2019 Jul; 98(27):e16298. PubMed ID: 31277165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes.
    Billiet C; De Ruysscher D; Peeters S; Decaluwé H; Vansteenkiste J; Dooms C; Deroose CM; De Leyn P; Hendrikx M; Bulens P; Le Péchoux C; Mebis J
    J Thorac Oncol; 2016 Sep; 11(9):1538-49. PubMed ID: 27374454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.
    Brandt WS; Yan W; Leeman JE; Tan KS; Park BJ; Adusumilli PS; Bott MJ; Molena D; Isbell J; Chaft J; Rimner A; Jones DR
    Ann Thorac Surg; 2018 Sep; 106(3):848-855. PubMed ID: 29807005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.
    Rajaram R; Correa AM; Xu T; Nguyen QN; Antonoff MB; Rice D; Mehran R; Roth J; Walsh G; Swisher S; Hofstetter WL; Vaporciyan A; Cascone T; Tsao AS; Papadimitrakopoulou VA; Gandhi S; Liao Z; Sepesi B
    Clin Lung Cancer; 2020 Jul; 21(4):e294-e301. PubMed ID: 32089476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
    Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
    Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.
    Sawabata N; Keller SM; Matsumura A; Kawashima O; Hirono T; Osaka Y; Maeda H; Fukai S; Kawahara M;
    Lung Cancer; 2003 Oct; 42(1):69-77. PubMed ID: 14512190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy.
    Wang W; Men Y; Wang J; Zhou Z; Chen D; Xiao Z; Feng Q; Lv J; Liang J; Bi N; Gao S; Wang L; Hui Z
    BMC Cancer; 2019 May; 19(1):478. PubMed ID: 31113432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
    Graeter TP; Sebastian B; Bischof M; Kugler G; Fischer JR; Schneider T
    Thorac Cardiovasc Surg; 2016 Sep; 64(6):501-6. PubMed ID: 26322832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
    Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
    Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group.
    Johnstone DW; Byhardt RW; Ettinger D; Scott CB
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):365-9. PubMed ID: 12243809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?
    Casiraghi M; Guarize J; Sandri A; Maisonneuve P; Brambilla D; Romano R; Galetta D; Petrella F; Gasparri R; Gridelli C; De Marinis F; Spaggiari L
    Clin Lung Cancer; 2019 Mar; 20(2):97-106.e1. PubMed ID: 30446406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
    Bunn PA
    Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative concurrent chemoradiotherapy followed by extrapleural pneumonectomy for patients with non-small cell lung cancer with malignant pleural effusion and/or pleural nodules: Ten-year results of a prematurely terminated single institute phase II trial.
    Yamaguchi M; Ichinose Y; Shimamatsu S; Yoshida T; Toyokawa G; Nosaki K; Hirai F; Seto T; Takenoyama M
    Surg Oncol; 2015 Jun; 24(2):78-83. PubMed ID: 25818753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.